Akero Therapeutics, Inc. (AKRO)
Dec 9, 2025 - AKRO was delisted (reason: acquired by NVO)
54.65
0.00 (0.00%)
Inactive · Last trade price on Dec 8, 2025
Akero Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Akero Therapeutics stock had an average target of 73.56, with a low estimate of 54 and a high estimate of 109.
Price Target: $73.56 (+34.60%)
Analyst Consensus: Buy
* Price targets were last updated on Oct 10, 2025.
Analyst Ratings
The average analyst rating for Akero Therapeutics stock from 11 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 5 | 5 | 5 |
| Buy | 3 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 8 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Suspends n/a | Buy | Suspends | n/a | n/a | Dec 10, 2025 |
| Wolfe Research | Wolfe Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Oct 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $72 → $54 | Strong Buy → Hold | Downgrades | $72 → $54 | -1.19% | Oct 10, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $75 → $56 | Strong Buy → Hold | Downgrades | $75 → $56 | +2.47% | Oct 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $73 → $54 | Strong Buy → Hold | Downgrades | $73 → $54 | -1.19% | Oct 9, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.79
from -3.75
EPS Next Year
-4.40
from -3.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.77 | -4.18 | ||||
| Avg | -3.79 | -4.40 | ||||
| Low | -3.86 | -4.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.